Advertisement
Singapore markets close in 5 hours 58 minutes

  • Straits Times Index

    3,308.38
    +11.49 (+0.35%)
     

  • Nikkei

    38,236.07
    -37.98 (-0.10%)
     

  • Hang Seng

    18,376.31
    +169.18 (+0.93%)
     

  • FTSE 100

    8,172.15
    +50.91 (+0.63%)
     

  • Bitcoin USD

    59,557.21
    +2,147.67 (+3.74%)
     

  • CMC Crypto 200

    1,283.18
    +12.43 (+0.98%)
     

  • S&P 500

    5,064.20
    +45.81 (+0.91%)
     

  • Dow

    38,225.66
    +322.37 (+0.85%)
     

  • Nasdaq

    15,840.96
    +235.48 (+1.51%)
     

  • Gold

    2,309.90
    +0.30 (+0.01%)
     

  • Crude Oil

    79.07
    +0.12 (+0.15%)
     

  • 10-Yr Bond

    4.5710
    -0.0240 (-0.52%)
     

  • FTSE Bursa Malaysia

    1,585.43
    +5.13 (+0.32%)
     

  • Jakarta Composite Index

    7,098.12
    -19.31 (-0.27%)
     

  • PSE Index

    6,641.10
    -5.45 (-0.08%)
     

Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Apellis Pharmaceuticals, Inc.
·1-min read
Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc.

WALTHAM, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024, at 12:45 p.m. ET.

The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first and only therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.

Investor Contact: 
Meredith Kaya 
meredith.kaya@apellis.com
617.599.8178